Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
Completed · Not applicable · NCT02923726
Conditions: Sudden Cardiac Death
At a glance
- Research payments reported, 2025
- $6,196
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 2,692
About the trial
- Sponsor
- Boston Scientific Corporation
- Tested
- Arm 1 (ATP+Shock) (device), Arm 2 (shock only) (device)
- Dates
- Started 2016-09-30; completion 2023-07-06
- Results posted
- Yes
The primary objective is to understand the role of antitachycardia pacing (ATP) in primary prevention patients indicated for implantable cardioverter-defibrillator (ICD) therapy and programmed according to current guidance of higher rate cut-offs and therapy delays. The time to first all-cause shock will be tested in subjects with standard therapy (ATP and shocks) compared to subjects programmed to shock only to assess equivalency.
From ClinicalTrials.gov, last updated 2024-10-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Boston Scientific Corporation reported $6,196 in research payments for this study in 2025 (3 payments).
Products named: General - Brady
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Prashant D. Bhave, MD Cardiac Electrophysiology · Winston Salem, NC
- Erich L. Kiehl, M.D. Cardiac Electrophysiology · Newport News, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sentara Norfolk General Hospital, VA $3,306
- Wake Forest University Health Sciences $2,890
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.